Identifying a molecular target is essential for tumor-targeted nanomedicine. Current cancer nanomedicines commonly suffer from poor tumor specificity, "off-target" toxicity, and limited clinical efficacy. Here, we report a method to screen and identify new molecular targets for tumor-targeted nanomedicine based on a quantitative analysis. In our proof-of-principle study, we used comparative flow cytometric screening to identify ICAM-1 as a potential target for metastatic melanoma (MM). We further evaluated ICAM-1 as a MM targeting moiety by characterizing its (1) tumor specificity, (2) expression level, (3) cellular internalization, (4) therapeutic function, and (5) potential clinical impact. Quantitation of ICAM-1 protein expression on cells and validation by immunohistochemistry on human tissue specimens justified the synthesis of antibody-functionalized drug delivery vehicles, which were benchmarked against appropriate controls. We engineered ICAM-1 antibody conjugated, doxorubicin encapsulating immunoliposomes (ICAM-Dox-LPs) to selectively recognize and deliver doxorubicin to MM cells and simultaneously neutralize ICAM-1 signaling via an antibody blockade, demonstrating significant and simultaneous inhibitory effects on MM cell proliferation and migration. This paper describes a novel, quantitative metric system that identifies and evaluates new cancer targets for tumor-targeting nanomedicine.
Introduction
Tumor-targeted nanomedicines have the potential to mitigate the spatial and temporal challenges of therapeutic delivery to primary tumors and metastatic lesions via tumor recognition [1] [2] [3] [4] . For example, MM-302 (human epidermal growth factor receptor 2 (HER2) antibody-conjugated liposomal doxorubicin), a receptor targeting immunoliposome, has recently demonstrated clinical benefits for HER2-positive metastatic breast cancer patients by significantly improving median progression free survival by 7.6 months and demonstrating an overall patient response rate of 11% [5] [6] [7] [8] [9] . However, other aggressive cancers, such as metastatic melanoma (MM) and pancreatic cancer, have no or limited clinically effective targets [10] [11] [12] [13] [14] . On these cancer cell membranes, hundreds of different proteins are upregulated or downregulated to promote cancer development and progression.
Choosing an appropriate target is a critical parameter, therefore, in the development of tumor-targeted nanotherapeutics, which impacts therapeutic biodistribution, efficacy, and safety. To date, there remains a lack of quantitative studies to systematically identify, evaluate, and validate cancer targets for nanotherapeutics.
The goal of our study is to develop an unbiased method to screen and identify molecular targets that may be useful for tumor-targeting. A flowchart of the procedures for this method is shown in Fig. 1 . First, we applied comparative flow cytometric screening to profile the expression of cancer-related cell surface antigens on cancer cells and their noncancerous (control) counterparts. Candidates were ranked and selected based on the level of overexpression. Second, the screened candidate was evaluated as a molecular target for tumor-targeted nanomedicine by characterizing its (1) tumor specificity, (2) expression level, (3) cellular internalization, (4) therapeutic function and (5) potential clinical impact. Third, we validated the effectiveness of the identified target by constructing tumor-targeted immunoliposomes conjugated with antibodies recognizing the target and measuring their tumorspecific affinity and half maximal inhibitory concentration (IC50).
In this study, we focused our attention on MM, the most fatal skin cancer [15] [16] [17] [18] . The methodology presented here identifies parameters necessary for evaluating a potential therapeutic target to disrupt cancer pathogenesis, and offers the opportunity to systematically and quantitatively, in an unbiased way, discover molecular targets for nanomedicine applications.
Experimental section

Materials
Dulbecco's phosphate buffered saline (PBS), 4′,6-diamidino-2-phenylindole (DAPI), 0.25% trypsin/2.6 mM ethylenediaminetetraacetic acid (EDTA) solution, Gibco® Dulbecco's Modified Eagle Medium (DMEM), Gibco®DMEM/F12(1:1) were purchased from Invitrogen (Carlsbad, CA, USA). Quantum Simply Cellular microbeads were purchased from Bangs Laboratory (Fishers, IN, USA). Mouse antihuman ICAM-1 monoclonal antibody, immunoglobulin G (IgG) isotype controls were purchased from R & D Systems (Minneapolis, MN, USA). For antibodies used in flow cytometric analysis, Phycoerythrin (PE)-conjugated mouse anti-human VEGFR1, VEGFR2, and FLOR1 antibodies were purchased from R & D Systems, and all other PE-conjugated antibodies and PE-conjugated mouse or rat IgG isotype controls were purchased from BioLegend (San Diego, CA, USA). Human melanoma tissue (ME2080b, T382a and T386) and normal tissue (BN00011 and BN1002a) arrays were purchased from US Biomax (Rockville, MD, USA). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), bovine serum albumin (BSA), anhydrous dimethyl sulfoxide (DMSO) were purchased from SigmaAldrich (St. Louis, MO, USA). Slide-A-Lyzer™ Dialysis Cassette (MWCO 20 kDa), Corning Costar Transwell Permeable Supports and Lab-Tek II Chamber Slide System were obtained from Thermo Fisher Scientific (Pittsburgh, PA, USA). Fluorogel with tris buffer was purchased from Electron Microscopy Sciences (Hatfield, PA, USA). RNeasy mini kit was purchased from Qiagen (Valencia, CA, USA).
Cell culture
A375SM human metastatic melanoma was obtained from Dr. Isaiah J. Fidler (MD Anderson Cancer Center, Houston, TX, USA) [19, 20] . C32 human metastatic melanoma was obtained from American Type Culture Collection (ATCC, Manasses, VA, USA) [21] [22] [23] . Adult human epidermal melanocytes from lightly-pigmented skin (HEMa-LP, normal human melanocytes) were purchased from Cascade Biologics (Invitrogen). A375SM and C32 cells were cultured in DMEM, normal human melanocytes in MGM™-4 melanocyte growth medium (Lonza, Portsmouth, NH, USA), with all recommended supplements, respectively. All cells were maintained at 37°C in a humidified incubator with 5% CO 2 .
Flow cytometry measurement
Cell membrane expression of molecular target candidate was evaluated by a BD FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA) as described previously [24] . Quantification of the molecular target density on the cell surface was determined with reference to Quantum Simply Cellular microbeads, using the protocol as provided by the manufacturer. Briefly, 10 6 cells were collected and rinsed twice through suspension-spin cycles. Cells were blocked by 1% bovine serum albumin (BSA) in PBS for 30 min in an ice bath. After BSA blocking, cells were incubated with PE-conjugated antibodies for 1 h at RT. Cells were rinsed with 1% BSA in PBS three times, resuspended in PBS, and evaluated by flow cytometry.
Quantitative analysis of MM cell binding and uptake of synthesized liposomes was studied by flow cytometry analysis. 10 6 cells were placed in each well of a 6-well cell culture plate and incubated for 2-4 h at 37°C with (1) rhodamine-dextran (RD)-encapsulating, nonspecific IgG conjugated liposome (IgG-RD-LP), (2) RD-encapsulating ICAM-1 antibody conjugated liposome (ICAM-RD-LP) at a final concentration of 1 μM lipids per 10 6 cells. All liposome-treated cells were washed with PBS, harvested using a 0.25% trypsin/2.6 mM EDTA solution, and washed with PBS three times. Binding data were acquired using a BD FACSCalibur flow cytometer and analyzed using FlowJo software. The specific cell uptake of ICAM-RD-LP with reference to non-specific IgG-RD-LPs was calculated by dividing the mean fluorescence intensity of ICAM-RD-LP stained cells by that of the IgG-RD-LP stained cells.
Immunohistochemistry
162 human melanoma tissue samples and 178 normal human tissue samples from 20 different organs were stained and evaluated for ICAM-1 expression level and tumor specificity. Immunohistochemical staining was performed on paraffin-embedded human melanoma tissue microarrays (ME2080b, T382a and T386) and normal tissue microarrays (BN00011 and BN1002a). The individual tissue cores in the microarrays were scored by an independent pathologist, with no knowledge of sample identity, for no staining (0), weak staining (1 +), moderate staining (2 +), or strong staining (3 +). Photomicrographs were taken on an Olympus BX41 microscope by using an Olympus Q-Color5 digital camera (Olympus America, Center Valley, PA, USA).
Immunofluorescent staining
A375SM, C32 or human melanocytes (2 × 10 5 cells) were seeded in a LabeTek II Chamber Slide System with 2 mL media overnight at 37°C. After media was removed, cells were rinsed with PBS three times and fixed with 4% formaldehyde in PBS at RT for 10 min, followed by three rinses with PBS. Samples were blocked with 1% BSA in PBS for 30 min in an ice bath. After BSA blocking, samples were stained with PE-conjugated ICAM-1 antibodies or PE-conjugated control IgG for 1 h and rinsed with PBS. DAPI was used to stain the cell nuclei. Immunofluorescent stained samples were dried overnight in the dark and examined under a Leica TCS SP5 confocal fluorescent microscope (Leica Microsystems, Buffalo Grove, IL, USA). Digital images were captured with AxioVision digital image processing software. 
qRT-PCR
The mRNA expression levels of ICAM-1 in MM cells were analyzed using qRT-PCR. A375SM, C32 and human melanocyte cells were cultured at 10 6 cells/well in 6-well cell culture plates overnight. Cells were then removed from each well by incubating with a trypsin/EDTA solution for 3 min. The cells were washed with PBS for three times. RNA was extracted, purified using the Qiagen RNeasy mini kit, and quantified using a SpectraMaxPlus 384 UV-Visible Spectrophotometer (Molecular Devices Corp, Sunnyvale, CA, USA). Reverse transcription was conducted using the Applied Biosystems Taqman RT protocol. Detection and quantification of mRNA were performed using the StepOnePlus Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). All PCR samples were referenced to the gene expression of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Cell proliferation
Human MM cells (A375SM and C32) were pre-seeded in 96-well plates (5 × 10 3 cells/well). After 24-h incubation, cells were treated with 10 μg/mL of IgG or ICAM-1 antibodies in DMEM with 10% fetal bovine serum (FBS) for 24 h. Then IgG or ICAM-1 antibody-treated cells were rinsed twice with PBS, and grown in DMEM with 10% FBS. At day 1, 3, and 5 after treatment, cell viability was determined by a Dojindo cell counting kit using the protocol from the manufacturer (Dojindo Molecular Technologies, Rockville, MD, USA). To evaluate the cytotoxicity of immunoliposomes, cells were treated with (1) PBS, (2) Free Dox, (3) non-specific IgG-conjugated, Dox-encapsulating liposomes (IgG-Dox-LPs), (4) ICAM-1 antibody-conjugated, Dox-encapsulating liposomes (ICAM1-Dox-LP) at the equivalent Dox dosage of 0, 0.08, 0.4, 2, 10, 50 μg/mL for 6 h. Cells were rinsed twice with PBS and grown for 48 h before the Dojindo assay.
Cell migration
Human MM cell migration was measured as described previously [25] . Briefly, A375SM and C32 cells were pre-treated with the following samples: IgG, ICAM-1 antibody, IgG-LP, ICAM-LP for 24 h, and then seeded onto COSTAR migration inserts with permeable support polycarbonate membrane (8 μm pore size) in a 24-well plate at a cell density of 10 5 cells per well in DMEM without FBS. DMEM with 10% FBS was added to the lower wells. The cells were allowed to migrate for 20 h. The inserts were stained with Diff-Quik Stain Set and the cells that did not migrate through the insert membranes were removed using cotton swabs. Four fields/insert were counted for each sample.
ICAM-Dox-LP synthesis and characterization
The ICAM-1 targeted, Dox-encapsulating immunoliposome was prepared by the transmembrane gradient assay as described previously [26, 27] . Briefly, a lipid formulation consisting of DOPC:DSPE-PEG-COOH (95:5, mol:mol) was used to prepare liposomes. 50 mmol lipid mixture was solubilized in chloroform and dried under a dry nitrogen stream. The resulting lipid film was dissolved in 1 mL DMSO:EtOH (7:3, v:v). The lipid solution was injected in 9 mL of 240 mM PBS while being rigorously agitated to yield a 5 mM lipid solution. After 10 freeze-thaw cycles, lipid solution was extruded via a NorthernLipids Extruder with a 100 nm polycarbonate nanoporous membrane. After extrusion, the liposome solution was dialyzed in PBS using a Slide-A-Lyzer dialysis cassette (MWCO 20 kDa) overnight at room temperature (RT). Then Dox was added to liposome solution to reach a final concentration of 200 μg/mL, and incubated for 6 h to facilitate active loading. The resulting Dox-encapsulating liposome solution was dialyzed in PBS using a Slide-A-Lyzer dialysis cassette (MWCO 20 kDa) overnight at RT.
The surface of Dox-encapsulating liposomes was modified with the ICAM-1 antibodies via the DSPE-PEG-COOH anchor. EDC (2 mg) and NHS (3 mg) were mixed with 1 mmol of lipid (liposomes) in PBS and incubated for 6 h at RT. A Slide-A-Lyzer dialysis cassette (MWCO 10 kDa) was used to remove unreacted EDC and NHS. Next, ICAM-1 antibody or the IgG isotype was added to EDC-modified liposomes at a molar ratio of 1:1000 (antibody:phospholipid) and incubated overnight at RT. Unreacted antibodies were removed by using a FLOAT-A-LYZER G2 dialysis tubing (MWCO 300 kDa). In liposome binding experiments, non-cytotoxic rhodamine-dextran encapsulating liposomes (ICAM-RDLPs) were prepared and tested to replace the cytotoxic ICAM-Dox-LPs. The preparation process was similar as ICAM-RD-LP with the exception being that the 1 mL lipid solution was added to a 9 mL rhodaminedextran solution (1 mg/mL).
The density of ICAM-1antibodies conjugated on liposomes was quantified via microbead assay as described previously [25] [26] [27] . Liposomes cannot be detected by flow cytometry because of their size, therefore, 2 μm borosilicate beads were encapsulated within DOPC:DSPE-PEG-COOH (95:5, mol:mol) liposomes by sonicating small unilamellar liposomes with microbeads in PBS for 6 h. Microbeads were rinsed three times in PBS via suspension-spin cycles to separate free liposomes. Conjugation of PE-ICAM-1 antibody or PE-IgG (nonspecific binding) to microbead encapsulating liposomes was performed using EDC/NHS chemistry. The surface density of ICAM-1 antibody conjugated to each microbead was determined with reference to Quantum Simply Cellular microbeads, which have defined numbers of antibody binding sites per bead. Liposome size and zeta potential were measured by dynamic light scattering on a Zeta-PALS analyzer (Brookhaven Instruments, Holtsville, NY, USA) in PBS.
Statistical analysis
All experimental data were obtained in triplicate unless otherwise mentioned and are presented as mean ± standard deviation. Statistical comparison by analysis of variance was performed at a significance level of P < 0.05 using Student's t-test.
Results and discussion
Screening of targets of MM cell lines
In order to identify targets for MM-specific nanomedicine, we constructed a cancer target panel that consists of 44 cancer-related cell membrane proteins (Table S1 ). These cancer target candidates were selected by three criteria: (1) cell membrane proteins, which are more desirable targets in comparison to intracellular or secreted proteins because they can be directly accessed by the nanomedicine for tumor recognition and may aid in internalization of the nanomedicine via receptor-mediated endocytosis, (2) low expression in healthy vital organs (e.g. lung, liver, kidney and heart), and (3) involvement in cancer development and progression. This panel includes several clinically-used cancer targets (e.g. HER2, epidermal growth factor receptor (EGFR) [28, 29] , and vascular endothelial growth factor receptors (VEGFRs)) and recently identified MM targets (e.g. CD44 [30, 31] and Integrin αvβ3 (ITGAVB3) [32, 33] ). We used comparative flow cytometric analysis to profile the surface expression levels of these cell membrane proteins in two human MM cell lines (A375SM and C32) [19] [20] [21] [22] [23] and normal human melanocytes (control). We chose to use comparative flow cytometry to screen potential targets for MM-specific nanomedicine over other conventional screening assays (e.g., PCR array and mass spectrometry) because this method is unique in utilizing antibody-antigen interactions to precisely quantify the surface expression of cell membrane proteins on live cancer cells. This approach closely recapitulates the interaction between tumor and antibodydirected nanomedicine in vivo. Such information cannot be obtained by other screening methods. Obtained MM target candidates were ranked based on their average overexpression levels on MM cells relative to normal human melanocytes (Fig. 2a) . The top 10 most overexpressed candidates on A375SM and C32 cells are listed in Fig. 2b and c, respectively. ICAM-1, TFRC, ITGAVB3, and ITGA6 emerged as four highly overexpressed cell surface targets on both A375SM and C32 cells. We also compared the expression levels of these two sets of top 10 candidates on normal human melanocytes (Fig. 2d) . ICAM-1, TFRC, and ITGA6 demonstrated lower cell surface densities in normal melanocytes, in comparison with ITGAVB3 and other candidates, suggesting that ICAM-1, TFRC and ITGA6 are three potential MM targets. We focused on ICAM-1 because it has the lowest expression in normal human tissues (13 of 45 types of organs) compared with TFRC (39 of 45) and ITGA6 (33 of 45) according to Human Protein Atlas database (www.proteinatlas.org). ICAM-1 is a cell membrane glycoprotein involved in immunological cascades with important roles in regulating cell adhesion [24, 34, 35] , and previous work in human tissues also suggested that ICAM-1 may play an important role in melanoma metastasis development [36] [37] [38] [39] [40] .
Evaluation of ICAM-1 for MM-specific nanomedicine
Tumor specificity
The primary role of a targeting moiety is to discriminate between the tumor and the healthy tissues. We evaluated the tumor specificity of ICAM-1 by quantitatively analyzing its expression level in 162 cases of human melanoma (including 67 cases of MM (Stage IV) and 95 cases of non-metastatic melanoma (non-MM, Stages I-III)) and 178 cases of normal human tissues (covering 20 types of organs) via immunohistochemical (IHC) staining. As shown in Fig. 3a , ICAM-1 was significantly upregulated in melanoma tissues as compared with most normal tissues. ICAM-1 was also present in 6 of 20 normal human organs: bone, lung, lymph node, spleen, testis, and thymus. Though this is not optimal, our findings correlate with the Human Protein Atlas database, which reported that ICAM-1 expression in normal organ tissues is substantially less than those of CD44 and ITGAVB3, two widely accepted melanoma targets [41, 42] . Overexpression of ICAM-1 in 162 human melanoma tissues provides clinically-relevant evidence supporting ICAM-1 as a promising molecular target for melanoma.
We also compared the tumor specificity of ICAM-1 protein expression (IHC scores) with ICAM-1 gene expression (Fig. 3b) in an independent validation cohort of MM patient tumors (n = 44) and various normal organs (n = 486) via R2: Genomics Analysis and Visualization Platform database (r2.amc.nl/). High ICAM-1 expression was found in normal lung tissues at both protein and gene levels, which may be a potential off-target site for ICAM-1 antibody-guided nanomedicine. Our previous animal studies demonstrated that ICAM-1 antibody-guided iron oxide nanoparticles did not target normal lung during circulation [24] . In addition, we also evaluated the potential interaction between ICAM-1 antibody-directed nanomedicine and the immune system by using the same database. In Fig. 3c , we analyized the ICAM-1 gene expression levels on 13 different types of immune cells including both innate and adaptive leukocytes. Among these cell types, 
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only monocytes demonstrated a comparative ICAM-1 gene expression to MM tumors (approximately 71%). Due to the low number of monocytes in the blood circulation (usually comprising 2-8% of leukocytes), it may not have a strong interference on the MM tumor targeting activity of ICAM-1 antibody-directed nanomedicine. We also found that hematopoietic stem cells from the bone marrow, which give rise to all leukocytes, have a significantly lower gene expression of ICAM-1 compared with MM tumors.
Expression level
Overexpression of the target molecule is indicative of preferential nanomedicine binding to the desired cell type and therefore increased effectiveness of tumor-specific drug delivery [25, 26, [43] [44] [45] [46] [47] . The overexpression of ICAM-1 was quantified in 162 cases of human melanoma tumor tissues and two human MM cell lines (A375SM and C32). ICAM-1 in human melanoma tissues was stained and scored by an independent pathologist. As shown in Fig. 4a , strong ICAM-1 staining was observed in both non-metastatic and metastatic melanoma tissues, but was absent in normal skin tissues. Enlarged images in Fig. 4a further revealed that ICAM-1 predominantly localized on melanoma cell membranes, which is accessible for nanomedicine binding. Quantified IHC scores in Fig. 4b show that ICAM-1 was significantly overexpressed in 95 cases of human non-metastatic and 67 cases of metastatic melanoma relative to normal skin tissues. There is no significant difference in ICAM-1 levels between non-metastatic and metastatic melanoma tissues, suggesting that ICAM-1 may play important oncogenic roles at both early and late stages of this disease.
We measured ICAM-1 expression levels in two human MM cell lines (A375SM and C32) as well as normal human melanocytes via qRT-PCR (Fig. 4c) . mRNA levels of ICAM-1 in A375SM and C32 cells were 6 and 11-fold higher than that of normal human melanocytes, respectively. ICAM-1 surface density on A375SM and C32 was measured by flow cytometric analysis as 697,000 ± 8250 and 1,059,000 ± 4600 molecules/cell, respectively (Fig. 4d) . In contrast, normal melanocytes only expressed 58,000 ± 1500 molecules/cells, > 12-fold less than either of the MM cell lines. We validated the overexpression and surface localization of ICAM-1on these two MM cells by immunofluorescent staining where A375SM, C32 and normal human melanocytes were incubated with fluorophore-conjugated ICAM-1 antibodies (Fig. 4e) . Strong ICAM-1 staining was observed in A375SM and C32 cells but not in normal human melanocytes, indicating the selective binding of the ICAM-1 antibody to MM cells. The combined data from human melanoma tissues and cell lines consistently support that our identified target, ICAM-1, is abundantly expressed in MM at both protein and mRNA levels and may serve as a highly specific target for MM.
Internalization
Many therapeutic agents (e.g. proteins or nucleic acid drugs) are unable to spontaneously enter cancer cells [48, 49] . The capability of a nanomedicine to deliver its cargo across a cell membrane and access intracellular targets has a direct impact on its efficacy. Receptormediated internalization of ICAM-1 antibodies was detected in both A375SM and C32 cells via two independent measurements: immunofluorescent staining and flow cytometry. Confocal fluorescent images ( Fig. 5a and b) show that at the 10 min incubation time, fluorophoreconjugated ICAM-1 antibodies were mainly localized at the MM cell surface. At 120 min, ICAM-1 antibodies were endocytosed and distributed within endosomes in the perinucelar region. Flow cytometry data ( Fig. 5c and d ) also confirmed the increased internalization of ICAM-1 antibodies over time in both A375SM and C32 cells. Internalization of the ICAM-1 antibody in MM cells suggests it may mediate intracellular drug delivery. Because cell endocytosis is an ATP-driven process that is dramatically affected by temperature [50, 51] , we incubated MM cells at 4°C for 120 min after 10 min ICAM-1 antibody staining and found that the internalization process was significantly inhibited at 4°C (Fig. 5c and d) . This confirmed cell endocytosis of ICAM-1 antibodies.
Therapeutic function
ICAM-1 has previously been found to have an important role in promoting melanoma progression and metastasis [36] [37] [38] [39] [40] , we reasoned that ICAM-1 may not only serve as a target for MM recognition, but may also hinder disease progression. Using neutralizing antibodies to block ICAM-1 may therefore abrogate adhesion and subsequently a prometastatic phenotype. Similar effects were observed in our previous studies [24, 25] . For example, we have demonstrated that immunoliposomes modified with the CXCR4 neutralizing antibodies not only guided immunoliposomes to metastatic breast cancer cells but also impeded cancer cell migration via blockade of CXCR4-mediated signaling pathways [25] . Here, we examined the therapeutic function of ICAM-1 in two predominant malignant behaviors of MM: proliferation and migration. First, in MM cell proliferation studies (Fig. 6a and  b) , treatment with the ICAM-1 antibody (10 μg/mL) did not alter A375SM and C32 cell proliferation. However, as shown in Figs. 6c and d, the ICAM-1 antibody (10 μg/mL) did exhibit potent activity in inhibiting both A375SM and C32 cell migration via blocking ICAM-1. The number of migrated A375SM and C32 cells was significantly reduced by 74% and 85%, respectively, in comparison to cells treated with non-specific IgG. These findings demonstrate that an ICAM-1 antagonist such as a neutralizing antibody may be useful in blocking metastasis of MM.
Potential clinical impact
Due to the complexity and heterogeneity of tumors, it is essential to evaluate a broad array of patient specimens for our identified target. Tissue specimens were obtained from 162 melanoma patients and 25 normal controls for IHC staining. Demographic details of the patients included in the study are shown in Table 1 . The melanoma patient group consisted of 88 men and 74 women with a median age of 54.5 years (ranging from 7 to 88 years). Melanoma patients were divided into two groups: non-MM patient group and MM patient group, with a similar gender profile and median age. IHC was scored as follows: 0 for no staining; 1+ for partial membrane immunoreactivity in > 10% of cells; 2+ for weak to moderate complete membrane immunoreactivity in > 10% of cells; and 3+ for strong complete membrane immunoreactivity in > 10% of cells. Positive ICAM-1 staining was defined as an equivalent IHC score of 2 +; which was observed in 27 of 95 (28%) non-MM patients and 24 of 67 (36%) MM patients. Conversely, 0 of 25 (0%) normal skin tissue controls evaluated showed positive ICAM-1 staining. Overall, positive ICAM-1 staining was detected in 28% non-MM patient samples and 36% MM patient samples, whereas EGFR, another established target in the field, was only detected in approximately 11.4% of patient's tumors [28] . The melanoma patient population which presented positive ICAM-1staining (32% in total) may potentially benefit from ICAM-1 targeted therapy. Importantly, soluble ICAM-1 protein levels were significantly elevated in the serum of melanoma patients compared to those of healthy controls and correlated with the stage of disease [52, 53] , We therefore hypothesize that ICAM-1 may be used as a diagnostic biomarker to identify patients that may benefit from ICAM-1 targeted therapy. We next assessed the impact of ICAM-1 expression on MM patient survival in R2: Genomics Analysis and Visualization Platform metastatic melanoma datasheet (n = 44). Tumor ICAM-1 expression levels showed an inverse correlation with MM patient overall survival (OS, Fig. 7 ). High tumor ICAM-1 remarkably correlated with poor OS, suggesting that ICAM-1 is closely associated with the clinical outcome of MM.
Validation of ICAM-1 as both a delivery and therapeutic target for MM using engineered immunoliposomes
We engineered an ICAM-1-targeted, doxorubicin (Dox) encapsulating immunoliposome (ICAM-Dox-LP) by covalently conjugating ICAM-1 antibodies to the surface of liposomal doxorubicin (scheme shown in Fig. 8a ). Non-targeting liposomal doxorubicin (Doxil®) has previously failed in Phase II clinical trials for MM therapy due to its insufficient efficacy [54] . To be clinically successful, our ICAM-Dox-LPs were designed to improve efficacy by enabling them to selectively recognize and target MM cells (and spare normal cells) via the ICAM-1 antigenantibody interaction between ICAM-Dox-LP and MM cells. Dox was loaded within liposomes using the transmembrane gradient method [26] , leading to an encapsulation efficiency of > 90%. Non-specific IgG conjugated, Dox encapsulating liposomes (IgG-Dox-LP) were also prepared as non-targeting controls. As-synthesized ICAM-Dox-LP and IgG-Dox-LP exhibited similar hydrodynamic diameters of approximately 100 nm with a polydispersity index of approximately 0.1, indicating uniformity (Table 2) . Liposomes with diameters < 200 nm can avoid capture by the reticuloendothelial system (RES), extending their in vivo circulation time [55] . Additionally, their size is small enough so that they can accumulate in tumors by leaking through pores in the tumor vasculature, coined the enhanced permeability and retention effect [56] . The zeta potential of ICAM-Dox-LPs and IgGDox-LPs exhibited anionic surface charges, which was less than − 10 mV. MM-specific cytotoxicity of ICAM-Dox-LP was evaluated by measuring its half maximal inhibitory concentration (IC50) in human MM cells. In dose-dependent cytotoxicity studies with A375SM and C32 cells ( Fig. 8c and d) , ICAM-Dox-LPs showed significantly increased cytotoxicity than non-specific IgG-Dox-LP in both human MM cell lines. Empty immunoliposome vehicles (ICAM-LP) did not demonstrate any cytotoxicity, suggesting the ICAM-1 antibody conjugated immunoliposome itself was not cytotoxic. IC50s for ICAM-Dox-LP, IgG-Dox-LP, and free Dox, calculated by SigmaPlot 12.0 software, were 0.53, 1.74, and 0.71 μg/mL for A375SM, and 0.02, 0.33, and 0.01 μg/mL for C32, respectively. These data indicate that ICAM-Dox-LPs effectively killed MM cells via enhanced delivery of Dox to MM cells as compared to nontargeted liposomes, which was achieved by improving liposome binding and uptake via the specific ICAM-1 antibody-antigen interaction.
We also evaluated the therapeutic benefits of ICAM-1 blockade from ICAM-Dox-LP. Empty ICAM-or IgG-LPs (without Dox, at a liposomeconjugated antibody concentration of 10 μg/mL) were used in this study to assess the effects of ICAM-1 blockade on MM cell migration without interference from Dox cytotoxicity. Consistent with the results from free ICAM-1 antibody treatment (as shown in Fig. 6d) , migration of ICAM-LP treated cells was significantly reduced compared to that of IgG-LP treated cells for both A375SM and C32 (Fig. 8e and f) . ICAM-LPs efficiently inhibited A375SM and C32 cell migration by over 60% and 72%, respectively. These results demonstrate that our engineered ICAM-Dox-LPs may simultaneously block tumor metastasis by inhibiting MM cell migration through the neutralizing ICAM-1 antibody and kill cancer cells effectively with MM-selective delivery of Dox, which may lead to synergistic therapeutic effects in MM treatment.
Conclusion
In summary, we developed a general method to screen and identify molecular targets for tumor-targeted nanomedicine. In this proof-ofprinciple study, we applied flow cytometric screening in MM cells to compare 44 cancer-related cell membrane proteins and identified ICAM-1 as a promising target for MM-specific nanomedicine. We further determined ICAM-1′s targeting and therapeutic potential by measuring its tumor specificity, expression level, receptor-mediated cellular internalization, therapeutic functions and clinical heterogeneity with both human specimens and cancer cell lines. Importantly, our engineered ICAM-1-targeted liposomal doxorubicin, simultaneous inhibited MM cell proliferation and migration, validating the potential effectiveness of ICAM-1-targeted immunoliposome in MM treatment. Considering the fact that liposomal doxorubicin (Doxil® and Myocet®) are clinically safe and effective nanomedicines for metastatic ovarian and breast tumors, our target discovery platform holds potential in clinical translatability by identifying targets to increase the selectivity, while reducing the cytotoxicity and therefore improving the therapeutic efficacy of liposomal doxorubicin for MM and other cancers. Moreover, this quantitative screening and targeting strategy may be extended to other nanomedicine systems including solid lipid nanoparticles and polymeric nanocapsules.
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